RE:RE:RE:RE:Mr. Market is wrong on this?I'm not a subject matter expert but likely because BG is not a drug, and non toxic so a preclinical study was not needed; in addition there have been more than enough papers on the benefits of BG. If the experts at MHI agreed to put their name on this study, that's good enough for me. The only concern was it's interaction with statins, but with the change to allow some patients to use it as a stand alone therapy, we are more likely to have significantly positive results conducted using the good standard to show statistically significant results.
From Wikipedia:
The main goals of preclinical studies are to determine a starting, safe dose for first-in-human study and assess potential toxicity of the product, which typically include new medical devices, prescription drugs, and diagnostics. Minty_33 wrote: Ciao said...Every now and then I need to remind myself that the prize is still the BG pill....
Spin the wheel, because it could be a total flop. How come there has been zero pre-clinical data released? Can anybody on this board answer that? ......